BIOR News and Press, Biora Therapeutics Inc. From 03/30/23

Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse events indicated in 14-day tox study for targeted therapeutics program ...

2023-03-29 17:35:59 ET Major earnings expected after the bell on Thursday include: BlackeBerry Limited ( BB ) Skillz ( SKLZ ) Canoo ( GOEV ) IonQ ( IONQ ) Astra Space ( ASTR ) For further details see: Notable earnings after Thursday's close

2023-03-29 17:35:47 ET Biora Therapeutics ( NASDAQ: BIOR ) is scheduled to announce Q4 earnings results on Thursday, March 30th, after market close. The consensus EPS Estimate is -$1.45 and the consensus Revenue Estimate is $0.06M (-86.4% Y/Y). For further details se...

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022 financial results on Thursday, March 30, 2023 after th...

2023-03-16 10:03:57 ET Gainers: Lipella Pharmaceuticals ( LIPO ) +48% . ThermoGenesis Holdings ( THMO ) +34% . Genelux ( GNLX ) +14% . Homology Medicines ( FIXX ) +10% . Biora Therapeutics ( BIOR ) +7% . Losers: Esperi...

2023-03-16 08:13:55 ET ThermoGenesis Holdings ( NASDAQ: THMO ) +56% . PureCycle Technologies ( PCT ) +17% Q4 earnings call release JanOne  ( JAN ) +30% . UiPath  ( PATH ) +15% Q4 Earnings call release Biora Therapeutics ( ...

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB2 program, reporting an average bioavailability of 37% for semaglutide,...

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a...

This could be a hectic week in the stock market, whether you’re trading penny stocks or higher-priced stocks. If you read the article on what to watch this week , you already know what’s coming. Economic data, earnings, and one of the biggest events, the January FOMC meeting, wi...

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611 study titled “Potential effects of food on a novel Drug Delivery System (DDS) to deliver...